Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis

Completed · Phase 4

Conditions studied: Atopic Dermatitis

In brief

To evaluate the efficacy and safety of pimecrolimus cream 1% in its registered indication (treatment of patients \> 3 months of age with mild to moderate atopic dermatitis) This study is not enrolling patients in the United States.

Key facts

Study ID

NCT00150059

Run by

Novartis

Starts

2004-12-01

Expected to finish

2005-12-01

Last updated by the study team

2008-02-15

Who can join

Age: 0 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• This study is not being conducted in the United States — Investigative Site, Philippines

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.